The US regulatory agency has just started a priority review of Imfinzi (durvalumab), in combination with Pfizer and ...

FDA Commissioner nominee Heidi Overton deflected multiple questions about her willingness to stand up to pressure from ...

These specialised professionals work alongside sites to uncover recruitment challenges early, using clinical expertise and ...

Dazodalibep is one of the assets included in Amgen's near-$28 billion takeover of Horizon Pharma in 2023, which also gave it ...

Orca Bio's manufacturing facility in Sacramento, California. Orca Bio has become a commercial-stage company with the FDA approval of Tregzi, a cell-based immunotherapy designed to prevent graft-versus ...

Takeda's $300 million wager on Protagonist Therapeutics' rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off. The first phase 3 trial of the injectable hepcidin mimetic, ...

The Swiss pharma group has just reported topline results from the phase 3 IMAgINATION study of Factor B inhibitor sefaxersen ...

AI-powered drug discovery companies Enveda Biosciences and Basecamp Research have completed impressive funding rounds – worth ...

The FDA's experts looked at data from NHS-Galleri, as well as the US and Canadian PATHFINDER 2 study, which enrolled more than 35,000 subjects and showed that the test was able to increase cancer ...

The FDA has approved Eli Lilly's once-weekly basal insulin product Onswik for adults with type 2 diabetes, setting up a market tussle with Novo over its recently launched Awiqli. Onswik (insulin ...

Kyverna Therapeutics has reported new data with its cell therapy for the rare autoimmune disease stiff person syndrome (SPS), ...

Roche has revealed new phase 2 data with enicepatide (formerly CT-388), its potential rival to Eli Lilly's dual GIP/GLP-1 ...